Related Experiment Videos
Suppressive effect of chrysin on macrophage LC3B autophagy through miR-204-5p in diabetic atherosclerosis
Chiu-Mei Lin1,2, Bao-Wei Wang3, Wei-Jen Fang3
1Department of Emergency Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Insights
Flavonoid chrysin enhances macrophage autophagy marker LC3B presentation and reduces microRNA 204-5p under high glucose conditions, potentially preventing diabetic cardiovascular diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- Diabetic cardiovascular diseases involve complex interactions between autophagy and inflammation.
- The specific effects of flavonoid chrysin on macrophage autophagy and microRNA 204-5p regulation in hyperglycemia remain largely unexplored.
Purpose of the Study:
- To investigate the molecular mechanisms by which chrysin influences macrophage autophagy (LC3B) and microRNA 204-5p expression under hyperglycemic conditions.
- To evaluate the therapeutic potential of chrysin in a diabetic rat model of carotid artery balloon injury.
Main Methods:
- Macrophages were subjected to high-glucose (HG) stimulation.
- A STZ-induced diabetic rat model with carotid artery balloon injury was utilized.
- Techniques included reverse transcription-quantitative PCR, Western blotting, immunohistochemistry, and luciferase activity assays.
Main Results:
- Chrysin significantly increased LC3B presentation and decreased miR-204-5p levels in HG-stimulated macrophages.
- Chrysin, rapamycin, and mutant miR-204-5p enhanced LC3B presentation by suppressing miR-204-5p.
- In diabetic rats, chrysin treatment reduced neointimal hyperplasia and M1 polarization, though it suppressed LC3B presentation in vivo.
Conclusions:
- Chrysin modulates LC3B autophagy and miR-204-5p expression in macrophages under hyperglycemic stress.
- Chrysin demonstrates potential in preventing hyperglycemia-related cardiovascular diseases, specifically neointimal hyperplasia, by regulating miR-204-5p.
- Further research is warranted to elucidate the in vivo mechanisms of chrysin's action in diabetic cardiovascular complications.
Abstract:
Flavonoid chrysin possesses many biological properties. Autophagy and inflammation interact to cause diabetic cardiovascular diseases. However, whether chrysin affects macrophage autophagy and microRNA 204-5p regulation under hyperglycemic conditions remain unclear. In this study, we examined that the effects of chrysin on the molecular regulatory mechanisms of miR-204-5p in LC3B macrophage autophagy under hyperglycemic stimulation. Macrophages were cultured with 25 mM glucose for hyperglycemia stimulation. A diabetic rat model of carotid artery balloon injury was established. Reverse transcription and real-time quantitative polymerase chain reaction, Western blotting, immunohistochemical staining, and luciferase activity assay were performed. The results indicated that chrysin augmented the macrophage autophagy marker LC3B presentation under high-glucose (HG)-stimulation significantly, however, chrysin attenuated the miR-204-5p level in macrophage cultures. Treatment with chrysin, rapamycin or mutant miR-204-5p increased LC3B presentation through the suppression of miR-204-5p level in macrophage cultures under HG-stimulated condition. By luciferase activity assay, the combination of chrysin with mutant miR-204-5p reduced LC3B binding activity under hyperglycemic stress. Treatment with chrysin (100 mg/kg/day) and wild-type miR-204-5p considerably reduced the neointimal sizes by 46.3% and 36.3%, respectively, at 14 days after carotid artery balloon injury in STZ-induced diabetic rats; ameliorated M1 polarization simultaneously. However, by treating with chrysin suppressed LC3B presentation in diabetic rats. Our findings indicate, under hyperglycemic stress, chrysin regulates the presentation of LC3B autophagy in hyperglycemia-stimulated macrophage cultures and neointimal hyperplasia by mediating the miR-204-5p expression. The results imply that chrysin is potentially effective for preventing hyperglycemia related cardiovascular diseases.
Related Concept Videos
Atherosclerosis III: Management
Inflammation